Alfasigma in the news
Developing therapeutic solutions
Tamtam found 20 recent articles about Alfasigma.
- BOLOGNA: Alfasigma, proteste per il mancato confronto sul contratto integrativo | VIDEO
Alfasigma workers in Bologna protested over failed contract renewal talks and concerns about welfare and work conditions.
- Alfasigma, oggi sciopero e presidio. “Mancano le condizioni per trattare”
Alfasigma employees staged a strike and protest over unsatisfactory contract renewal conditions, focusing on production bonus issues.
- Alfasigma, sciopero per il contratto. Si fermano gli stabilimenti in Italia
Alfasigma's Italian workforce is striking over rejected contract demands amid high workloads and company growth.
- Mobilitazione in Alfasigma: altissima l'adesione allo sciopero e alle manifestazioni
Alfasigma faced a nationwide 8-hour strike with strong worker participation, halting production and demanding better industrial relations.
- Sciopero Alfasigma, forte adesione e attività bloccate
Alfasigma workers held a nationwide strike with strong union support, halting production over contract disputes and company policies on smart working and investment strategies.
- Farmaceutica, rottura del negoziato sull’integrativo in Alfasigma: è sciopero
Unions at Alfasigma have called a national strike after failed negotiations over contract terms and company policies.
- Alfasigma, il 26 gennaio sciopero nazionale e manifestazione a Bologna | Fedaiisf Federazione delle
Alfasigma employees plan a national strike and protest over failed contract talks, citing inadequate profit-sharing and unilateral work policy changes.
- Alfasigma gains neuro treatment; BridgeBio offers $550M in notes
Alfasigma secures global rights to a neurological treatment, enhancing its neurotherapeutic offerings.
- Alfasigma pens €125M deal for injectable form of HSV treatment
Alfasigma invested €125M to acquire rights and develop an injectable HSV encephalitis treatment from Innovative Molecules, expanding its specialty care portfolio.
- Alfasigma investe in una cura per malattie rare
Alfasigma invests in Innovative Molecules to develop and commercialize a rare disease drug for HSV encephalitis with exclusive rights to its parenteral formulation.
- 125-Million-Deal comes as a big surprise
Innovative Molecules and Alfasigma struck a €125 million deal for adibelivir's injectable HSV encephalitis treatment, splitting development rights and boosting Innovative Molecules' HSV program.
- Alfasigma ottiene i diritti esclusivi su adibelivir per via parenterale per il trattamento dell’encefalite da HSV
Alfasigma secured exclusive rights to develop adibelivir's parenteral form for treating rare, severe HSV encephalitis, addressing a critical unmet medical need.
- Alfasigma investe in Innovative Molecules e ottiene i diritti globali su adibelivir per l’encefalite da HSV
Alfasigma partners with Innovative Molecules to develop and commercialize adibelivir for treating HSV encephalitis, addressing a critical unmet medical need.
- Alfasigma: ampliato il portafoglio specialty care con una nuova terapia per l’encefalite da HSV
Alfasigma partners with Innovative Molecules to develop adibelivir, a novel therapy for severe HSV encephalitis, aiming to improve treatment outcomes.
- Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease | Corporate
Alfasigma obtained exclusive rights and invested in Innovative Molecules to develop adibelivir for treating the ultra-rare, severe HSV encephalitis, addressing a critical unmet medical need.
- Alfasigma acquisisce licenza mondiale per adibelivir contro encefalite da Hsv
Alfasigma licensed and invested in Innovative Molecules to develop adibelivir for treating HSV encephalitis and genital herpes.
- Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
Alfasigma obtained exclusive rights and invested in Innovative Molecules to develop adibelivir for treating the ultra-rare, severe HSV encephalitis.
- Alfasigma
Alfasigma, a leading Italian pharmaceutical company, opened a new 17 million euro R&D center in Pomezia to advance pharmaceutical technology and innovation.
- Ottavo posto: Turytes Spa, la società che controlla Alfasigma
Alfasigma, controlled by Turytes Spa, is a leading Italian pharmaceutical company with global operations and strong growth in key therapeutic areas.
- Sorrento - I traceur azzurri ospiti della 4ª riunione CVS 2025 di Alfasigma
Italian Parkour athletes attended Alfasigma's CVS 2025 meeting, where Alfasigma announced its 2024 sponsorship of the Federginnastica team.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Alfasigma?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies